Quarterly ResultApr 29, 2026, 04:40 PM
LUNG Q1 Revenue -9% to $20.6M; Net Loss $(0.33) EPS
AI Summary
Pulmonx Corp (LUNG) reported first quarter 2026 financial results, with worldwide revenue decreasing 9% year-over-year to $20.6 million. Despite the revenue decline, the company improved its gross margin to 78% and reduced its net loss to $13.7 million, or $(0.33) per share. Management noted early progress from refreshed U.S. commercial strategies and continued execution in international markets, reaffirming its full-year 2026 financial outlook.
Key Highlights
- LUNG Q1 2026 worldwide revenue decreased 9% to $20.6M.
- U.S. revenue decreased 7% to $13.3M.
- International revenue decreased 12% to $7.3M; excluding China, it increased 22%.
- Gross margin improved to 78% from 73% year-over-year.
- Net loss improved to $13.7M, or $(0.33) per share, from $14.4M, or $(0.36) per share.
- Adjusted EBITDA loss was $8.5M.
- Cash and cash equivalents totaled $61.6M as of March 31, 2026.
- Reaffirmed full-year 2026 revenue guidance of $90M to $92M.